Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Capital Expenditures: 2019-2024

Historic Capital Expenditures for Phathom Pharmaceuticals (PHAT) over the last 6 years, with Dec 2024 value amounting to $135,000.

  • Phathom Pharmaceuticals' Capital Expenditures fell 38.64% to $27,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $147,000, marking a year-over-year decrease of 75.70%. This contributed to the annual value of $135,000 for FY2024, which is 91.74% down from last year.
  • Phathom Pharmaceuticals' Capital Expenditures amounted to $135,000 in FY2024, which was down 91.74% from $1.6 million recorded in FY2023.
  • In the past 5 years, Phathom Pharmaceuticals' Capital Expenditures ranged from a high of $1.6 million in FY2023 and a low of $135,000 during FY2024.
  • In the last 3 years, Phathom Pharmaceuticals' Capital Expenditures had a median value of $1.0 million in 2022 and averaged $936,667.
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 217.38% in 2022, then slumped by 91.74% in 2024.
  • Phathom Pharmaceuticals' Capital Expenditures (Yearly) stood at $1.0 million in 2020, then tumbled by 68.46% to $328,000 in 2021, then surged by 217.38% to $1.0 million in 2022, then surged by 56.96% to $1.6 million in 2023, then crashed by 91.74% to $135,000 in 2024.